DUBAI-FUTURE-FOUNDATION
17.6.2024 11:14:26 CEST | Business Wire | Press release
Dubai is increasingly becoming a global center for artificial intelligence. To this end, the metropolis of the day after tomorrow on the Gulf has pledged to train one million people in AI prompting over the next three years with Dubai Future Foundation overseeing the AI prompt program.. It is the first program of its kind in the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240613025960/en/
Omar Al Olama, the UAE´s Minister of State for AI, Digital Economy, and Remote Work Applications. (Photo: Business Wire)
“We want to be the most future-ready city and continue to prepare for the AI era by developing expertise and skills that support global technological change and put Dubai at the forefront of innovation,” said the Chairman of the Board of Trustees of the Dubai Future Foundation (DFF), Crown Prince Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, at the launch of the 'One Million AI Prompters' initiative in Dubai.
The United Arab Emirates, in which Dubai is the most important emirate alongside Abu Dhabi, is preparing for the post-oil era and wants to transform itself from an oil state into an AI power. By 2031, 40 percent of the gross domestic product is to be generated with artificial intelligence. To this end, the UAE is investing billions, has appointed the world's first Minister of State for AI, is attracting scientists to the Gulf, and is providing massive support for start-ups.
AI prompt engineering is critical to getting the best out of generative AI. It involves understanding the capabilities, limitations, and nuances of AI models and is predicted to be one of the most important skills in the future workplace.
‘One Million AI Prompters’, the first-of-its-kind prompt engineering initiative, that prepares expertise and competencies in AI prompt engineering, which involves crafting precise and effective instructions for AI systems to achieve desired outcomes in various tasks, ranging from generating creative content to solving complex challenges.
"We want to show people that there is a full spectrum of use cases. Whether you are technical or non-technical, you can utilize these tools,” said Omar Al Olama, the UAE´s Minister of State for AI, Digital Economy, and Remote Work Applications. He also highlighted the importance of developing practical prompt engineering skills, as these are crucial for the workforce of tomorrow and for enhancing quality of life through AI. Al Olama was appointed as the world's first AI Minister of State in the UAE in 2017.
World Championship in AI Prompt in Dubai
To launch the ‘One Million AI Prompters’ initiative, the first Global Prompt Engineering Championship was recently held in Dubai. Participants competed in categories beyond traditional coding, such as literature and art, highlighting the broad applicability of AI tools. In AI, a prompt refers to a specific request to a language model (e.g. ChatGPT or others) that can provide the user with an answer or solution.
The Global Prompt Engineering Championship received thousands of entries from around 100 countries. Thirty finalists from 13 countries qualified to come to Dubai to compete for the title of best prompt engineer in the competition's three categories. The winners were Australian Megan Fowkes in the art category Indian Ajay Cyril, 33, for coding, and Aditya Nair, 34, in literature. The Dubai Centre for Artificial Intelligence (DCAI) provided one million dirhams, approximately 273,000 US dollars, in prize money for the three winners.
Global competition around the United Arab Emirates
The UAE is increasingly being courted as a strategic partner by global tech giants. Microsoft, Google, and IBM already took part in the first championship with workshops. However, other companies and countries have also expressed interest in AI collaborations. There has been an AI university in the UAE since 2019 and the sovereign wealth fund Mubadala has set up a $100 billion AI fund.
Microsoft recently invested $1.5 billion in G42, the leading UAE-based artificial intelligence (AI) technology holding company. The US software giant recognizes the Gulf state's leading role in the development of artificial intelligence: “This strategic investment will enhance the UAE’s position as a global AI hub and provide further opportunities for partners and customers to innovate and grow”.
For more information on the Global Prompt Engineering Championship, please visit:
https://challenge.dub.ai/en/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240613025960/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
